Document:

Exhibit
10.1

 

Wendy
Blosser

300
West Spring St. #1701

Columbus,
OH 43215

February
18, 2022

 

Dear
Wendy,

 

Proposed
appointment to Chief Executive Officer of Accustem Sciences, Inc.

 

It
gives me great pleasure to offer you the position as Chief Executive Officer of Accustem Sciences, Inc. (the “Company”) with
your employment scheduled to begin on March 4, 2022 (the “Effective Date”).

 

As
Chief Executive Officer, your duties will be ones normally associated with this position and such duties as are assigned to you from
time to time. This is a full-time position and you will be reporting directly to the Board of Directors. Your salary will be $425,000
per annum, payable in accordance with the Company’s standard payroll practices, which is to pay in equal semi-monthly instalments.

 

You
will be eligible to earn an annual cash bonus in the target sum equivalent to 45% of your base compensation, of which $47,813 shall be
guaranteed and paid in the first quarter of 2022. The remaining bonus will be subject to such conditions (including, but not limited
to, conditions based on your performance and that of the Company and conditions relating to the timing of payment) as we agree in the
annual review process, as part of which we will agree with you the precise criteria of the bonus conditions. The Company reserves the
right to not award a payment and the making of an award shall not oblige the Company to make any subsequent awards. You shall have no
right to be awarded, or where an award has been made, paid any bonus (pro rata or otherwise) if your employment has terminated. The precise
performance conditions for the bonus for the 2022 calendar year will be agreed between us as soon as is practicable and will based upon
progress achieved in accelerating and expediting the Company’s goals and commercialization programs.

 

The
Company will then, in the subsequent calendar year review process, review with you the progress towards your individual goals and the
quantum of the bonus to which you are eligible based on those goals.

 

Subject
to formal approval and issue we would expect you to receive on the Effective Date, an initial stock option award equal to 490,000 shares
of common stock of the Company with an exercise price equal to $2.13 per share.

 

    	 	-1-	 

     

    

 

Vesting
of 50% in aggregate of the options will be over four (4) years in tranches as follows, at the end of each year of completed service:

 

Year
1 – 10%

 

Year
2 – 10%

 

Year
3 – 10%

 

Year
4 – 20%

 

Vesting
of 25% of the options will be conditional on the Company completing a single equity fundraise which results in net proceeds to the Company
of not less than $30m.

 

Vesting
of the remaining 25% will be conditional on the Company launching a certified CLIA Lab in the US by the end of Q4 2023.

 

The
490,000 options are exactly equal (in value and percentage terms) to the 9,800,000 options that we had discussed in the context of the
former UK entity – on the corporate reorganisation we consolidated the old shares on a 20 into 1 basis and accordingly the 490,000
reflects the identical percentage of the share capital of the new US entity as it did of the UK entity.

 

All
share option awards are subject to the general rules of the Company’s share option plan.

 

Your
employment is subject to the Company’s personnel policies and procedures as they may be interpreted, adopted, revised or deleted
from time to time in the Company’s sole discretion. You will be eligible to participate on the same basis as similarly situated
employees in the Company’s benefit plans (if any) in effect from time to time during your employment, including a 401(k) plan.
All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the provisions of such
plan. The Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion.

 

You
will be expected to work an average of at least 40 hours per week during the Company’s normal business hours. As an exempt salaried
employee, you will be expected to work additional hours as required by the nature of your work assignments.

 

In
addition, the Company will offer participation in its medical, dental and vison benefit plans. Until the Company establishes a health
benefit plan, the Company will reimburse you for your monthly COBRA payment.

 

You
will be entitled to be reimbursed for your electronics such as cell phone or internet up to $200 per month.

 

The
Company shall reimburse you for use of your car on official Company
business. The reimbursement shall be paid monthly on the filing of a claim therefor by
you. You shall be reimbursed for any mileage travelled at a rate based upon the Internal Revenue
Service business mileage deduction rate.

 

Your
employment with the Company will be “at will” which means that either you or the Company may terminate your employment at
any time for any reason, with or without advance notice.

 

This
offer is contingent on your executing the Proprietary Information, Inventions, Non-Solicitation and Non-Competition Agreement which we
will provide.

 

This
offer is also subject to the results of references and a background check.

 

By
signing this letter, you are representing that you had and have full authority to accept this position and perform the duties of the
position without conflict with any other obligations and that you are not involved in any situation that might create, or appear to create,
a conflict of interest with respect to your loyalty to or duties for the Company. You specifically warrant that you are not subject to
an employment agreement or restrictive covenant preventing full performance of your duties to the Company. You agree not to bring to
the Company or use in the performance of your responsibilities at the Company any materials or documents of a former employer that are
not generally available to the public, unless you have obtained express written authorization from the former employer for their possession
and use. You also agree to honour all obligations to former employers during your employment.

 

By
signing this letter, you acknowledge that the terms described in this letter, together with the Proprietary Information, Inventions,
Non-Solicitation and Non-Competition Agreement attached hereto, set forth the entire understanding between us and supersedes any prior
representations or agreements, whether written or oral; there are no terms, conditions, representations, warranties or covenants other
than those contained herein. No term or provision of this letter may be amended waived, released, discharged or modified except in writing,
signed by you and an authorized officer of the Company, except that the Company may, in its sole discretion, adjust salaries, incentive
compensation, stock plans, benefits, job titles, locations, duties, responsibilities, and reporting relationships.

 

Please
indicate your acceptance of this offer by signing below and returning to me along with the executed Proprietary Information, Inventions,
Non-Solicitation and Non-Competition Agreement.

 

    	 	-2-	 

     

    

 

It
is likely that as a result of your position you may, from time to time, come into possession of material non-public information. You
will accordingly be required to adhere to the Company’s insider trading policy, a copy of which will be supplied to you.

 

You
will agree that all information, whether or not in writing, of a private, secret or confidential nature concerning the Company’s
business, business relationships or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive
property of the Company.

 

You
agree that you will not disclose any Proprietary Information to any person or entity other than employees or advisors of the Company
or use the same for any purposes (other than in the performance of your duties as a consultant and solely for the benefit of Company)
without written approval by an officer of the Company, either during or after you serve as an employee, unless and until such Proprietary
Information has become public knowledge without your fault.

 

You
also agree that any materials containing Proprietary Information which shall come into your custody or possession shall be and are the
exclusive property of the Company to be used only in the performance of your duties for the Company. All such materials or copies thereof
and all tangible property of the Company in your custody or possession shall be delivered to the Company upon the earlier of (i) our
request or (ii) termination of your participation as a consultant. After such delivery, you shall not retain any such materials or copies
thereof or any such tangible property.

 

You
agree that your obligations not to disclose or to use Proprietary Information and materials containing Proprietary Information and to
return materials and tangible property also extend to such types of information, materials and tangible property of customers of the
Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to you or the Company.

 

All
inventions, discoveries, data, technology, designs, innovations and improvements (whether or not patentable and whether or not copyrightable)
which are made, conceived, reduced to practice, created, written, designed or developed by you, solely or jointly with others, (i) in
connection with any meeting, discussions or negotiations with representatives of the Company if related to the business of the Company,
or (ii) if resulting or derived from Proprietary Information (collectively under clauses (i) and (ii), “Inventions”), shall
be the sole property of the Company. You hereby assign to the Company all Inventions and any and all related patents, copyrights, trademarks,
trade names, and other industrial and intellectual property rights and applications therefor, in the United States and elsewhere. You
agree to promptly notify the Company upon your first becoming aware of any of the following: (i) your invention or first reduction to
practice of any Invention; or (ii) the disclosure or misuse of any Proprietary Information.

 

The
validity, interpretation, construction and performance of this offer letter, and all acts and transactions pursuant hereto and the rights
and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware,
without giving effect to principles of conflicts of law. This offer letter sets forth the entire agreement and understanding of the parties
relating to the subject matter herein and supersedes all prior or contemporaneous discussions, understandings and agreements, whether
oral or written, between them relating to the subject matter hereof. This offer letter may be executed in any number of counterparts,
each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same
agreement.

 

If
the terms of your participation as set forth herein are acceptable, please sign where indicated below. Please return to me a signed copy
of this letter.

 

    	 	-3-	 

     

    

 

On
behalf of our board, I very much look forward to working together with you.

 

	Yours
    sincerely	 
	 	 
	/s/
    Gabriele Cerrone	 
	Gabriele
    Cerrone	 
	for
    and on behalf of	 
	Accustem
    Sciences, Inc.	 
	 	 
	ACCEPTED
    AND AGREED	 
	 	 
	Dated:
    	3/4/2022	
	 	 	 
	/s/
    Wendy Blosser	 
	Wendy
    Blosser	 
	(Signature)	 

 

    	 	-4-EX-4.4

  Exhibit 4.4

   

  DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

   

  The common stock, par value $0.0001 per share (the “Common Stock”), of Gemini Therapeutics, Inc. (“Gemini”, “we”, or “our”) is registered under Section 12 of the Securities Exchange Act of 1934, as amended.  The following description of our Common Stock is a summary and does not purport to be complete.  It is subject to and qualified in its entirety by reference to our Amended and Restated Articles of Incorporation (the “Charter”), our Amended and Restated Bylaws (the “Bylaws”) and the provisions of applicable law. The Charter and the Bylaws are incorporated by reference as an Exhibit 3.1 and 3.2, respectively, to the Annual Report on Form 10-K of which this Exhibit 4.4 is a part.   

   

  Authorized and Outstanding Stock

   

  The Charter authorizes the issuance of 260,000,000 shares, consisting of 250,000,000 shares of Common Stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value. 

   

  Common Stock

   

  The Charter provides the following with respect to the rights, powers, preferences and privileges of the Common Stock.

   

  Voting Power

   

  Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of Common Stock possess all voting power for the election of Gemini’s directors and all other matters requiring stockholder action. Holders of Common Stock are entitled to one vote per share on matters to be voted on by stockholders.

   

  Dividends

   

  Holders of Common Stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Board in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on Common Stock unless the shares of Common Stock at the time outstanding are treated equally and identically.

   

  Liquidation, Dissolution and Winding Up

   

  In the event of Gemini’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the Common Stock will be entitled to receive an equal amount per share of all of Gemini’s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied.

   

  Preemptive or Other Rights

   

  There are no sinking fund provisions applicable to the Common Stock.

   

  Preferred Stock

   

  The Board has the authority to issue shares of preferred stock from time to time on terms it may determine, to divide shares of preferred stock into one or more series and to fix the designations, preferences, privileges, and restrictions of preferred stock, including dividend rights, conversion rights, voting rights, terms of redemption, liquidation preference, sinking fund terms, and the number of shares constituting any series or the designation of any series to the fullest extent permitted by the General Corporation Law of Delaware (the “DGCL”). The issuance of preferred stock could have the effect of decreasing the trading price of Common Stock, restricting dividends on the capital stock of Gemini, diluting the voting power of the Common Stock, impairing the liquidation rights of the capital stock of Gemini, or delaying or preventing a change in control of Gemini.

   

  

   

  Election of Directors and Vacancies

   

  Subject to the rights of the holders of any series of preferred stock to elect additional directors under specified circumstances and the terms and conditions of the Voting Agreement, dated February 5, 2021, by and among us and the other parties thereto (the “Voting Agreement”), the number of directors of the Board shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board.

   

  Under the Bylaws, at all meetings of stockholders called for the election of directors, a plurality of the votes properly cast is sufficient to elect such directors to the Board.

   

  Except as the DGCL or the Voting Agreement may otherwise require and subject to the rights, if any, of the holders of any series of preferred stock, in the interim between annual meetings of stockholders or special meetings of stockholders called for the election of directors and/or the removal of one or more directors and the filling of any vacancy in that connection, newly created directorships and any vacancies on the Board, including unfilled vacancies resulting from the removal of directors, may be filled only by the affirmative vote of a majority of the remaining directors then in office, although less than a quorum, or by the sole remaining director. All directors will hold office until the expiration of their respective terms of office and until their successors will have been elected and qualified. A director elected or appointed to fill a vacancy resulting from the death, resignation or removal of a director or a newly created directorship will serve for the remainder of the full term of the class of directors in which the new directorship was created or the vacancy occurred and until his or her successor will have been elected and qualified.

  Subject to the rights, if any, of any series of preferred stock, any director may be removed from office only with cause and only by the affirmative vote of the holders of not less than two-thirds of the outstanding voting stock (as defined below) of Gemini then entitled to vote at an election of directors. Any such director proposed to be removed from office is entitled to advance written notice as described in the Charter. Subject to the terms and conditions of the Voting Agreement, in case the Board or any one or more directors should be so removed, new directors may be elected at the same time for the unexpired portion of the full term of the director or directors so removed.

   

  In addition to the powers and authorities hereinbefore or by statute expressly conferred upon them, the directors are empowered to exercise all such powers and do all such acts and things as may be exercised or done by Gemini, subject, nevertheless, to the provisions of the DGCL, the Charter and to any Bylaws adopted and in effect from time to time; provided, however, that no Bylaw so adopted will invalidate any prior act of the directors which would have been valid if such Bylaw had not been adopted.

   

  Notwithstanding the foregoing provisions, any director elected pursuant to the right, if any, of the holders of preferred stock to elect additional directors under specified circumstances will serve for such term or terms and pursuant to such other provisions as specified in the relevant certificate of designations related to the preferred stock.

   

  Quorum

   

  The holders of a majority of the voting power of the capital stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, will constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise required by law or provided by the Charter. If, however, such quorum will not be present or represented at any meeting of the stockholders, the holders of a majority of the voting power present in person or represented by proxy, will have power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum will be present or represented. At such adjourned meeting at which a quorum will be present or represented, any business may be transacted which might have been transacted at the meeting as originally noticed. If the adjournment is for more than thirty (30) days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting will be given to each stockholder entitled to vote at such adjourned meeting as of the record date fixed for notice of such adjourned meeting.

  Registration Rights

  Pursuant to the terms of our Registration Rights Agreement, dated February 5, 2021, with certain of our stockholders (the “Registration Rights Agreement”), certain of our stockholders are entitled to rights with respect to the registration of their shares (which we refer to herein a “Registrable Securities”) under the Securities Act of 1933, as amended (the “Securities Act”), including demand registration rights, shelf-registration rights and piggyback registration rights.

   

  

   

   

  				
	 
	•
	 
	Demand registration rights. At any time after February 5, 2021, and following the expiration of any lock- up to which a holder of Registrable Securities may have been subject, we are required, upon the written request of either (i) FS Development Holdings, LLC, Robert Carey, Daniel Dubin and Deepka Pakianathan  (collectively, the “FSDC Investors”) holding a majority of the Registrable Securities held by all FSDC Investors or (ii) Atlas Venture Fund X, L.P., Atlas Venture Opportunity Fund I, L.P., Lightstone Singapore L.P., Lightstone Ventures (A), L.P., Lightstone Ventures, L.P., OrbiMed Private Investments VI, LP and Wu Capital Investment LLC (collectively, “Major Gemini Investors” and together with the FSDC Investors, the “Investors”) holding a majority of the Registrable Securities held by all Major Gemini Investors, to file a registration statement under the Securities Act on Form S- 1 or any similar long-form registration statement or, if then available, on Form S-3, and use reasonable best efforts to effect the registration of all or part of their registrable securities requested to be included in such registration by the Investors.

    

  				
	 
	•
	 
	Shelf registration rights. We were required to file a shelf registration statement pursuant to Rule 415 of Securities Act, which was filed on February 17, 2021 and became effective on April 28, 2021. At any time we have an effective shelf registration statement, if we shall receive a request from Investors holding registrable securities with an estimated market value of at least $5,000,000, to effect an underwritten shelf takedown, we shall use our reasonable best efforts to as expeditiously as possible to effect the underwritten shelf takedown.

    

  				
	 
	•
	 
	Limits on demand registration rights and shelf registration rights.  We shall not be obligated to effect: (a)    more than one (1) demand registration or underwritten shelf takedown during any six-month period; (b) any demand registration at any time there is an effective resale shelf registration statement on file with the United States Securities and Exchange Commission; (c) more than two underwritten demand registrations in respect of all registrable securities held by the FSDC Investors, including those made under a shelf registration statement, or (d) more than two underwritten demand registrations in respect of all registrable securities held by the Major Gemini Investors, including those made under a shelf registration statement.

    

  				
	 
	•
	 
	Piggyback registration rights. At any time after February 5, 2022, if Gemini proposes to file a registration statement to register any of its equity securities under the Securities Act or to conduct a public offering, either for its own account or for the account of any other person, subject to certain exceptions, the Investors are entitled to include their registrable securities in such registration statement, subject to customary cut-back rights.

    

  				
	 
	•
	 
	Expenses and indemnification. All fees, costs and expenses of underwritten registrations will be borne by us and underwriting discounts and selling commissions will be borne by the holders of the shares being registered. The Registration Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and holders of registrable securities are obligated to indemnify us for material misstatements or omissions attributable to them.

    

  				
	 
	•
	 
	Registrable securities. Securities of the Company shall cease to be registrable securities upon the earlier of (i) tenth anniversary of February 5, 2021 and (ii) the date as of which (1) a registration statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed of in accordance with such registration statement, or (2) such securities shall have been transferred pursuant to Rule 144 of the Securities Act, or with respect to any Investor, securities of such Investor shall cease to be registrable securities, on the earlier of (x) the date such Investor ceases to hold at least 1% of the registrable securities or (y) if such Investor is an individual and such Investor is a director or an executive officer of the Company or FS Development Corp. as of immediately prior to the consummation of the business combination pursuant to the Merger Agreement, dated October 15, 2020, by and among us and the parties named therein, the date when such Investor is permitted to sell the Registrable Securities under Rule 144 (or any similar provision) under the Securities Act without limitation on the amount of securities sold or the manner of sale.

    

   

   

  

   

  Anti-Takeover Provisions

   

  Charter and Bylaws

   

  Among other things, the Charter and Bylaws:

   

  			
	 
	●
	permit the Board to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control;

	 
	 
	 

   

  			
	 
	●
	provide that the authorized number of directors may be changed only by resolution of the Board;

	 
	 
	 

   

  			
	 
	●
	provide that, subject to the rights of any series of preferred stock to elect directors, directors may be removed only with cause by the holders of at least 662/3% of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;

	 
	 
	 

   

  			
	 
	●
	provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;

	 
	 
	 

   

  			
	 
	●
	provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice;

	 
	 
	 

   

  			
	 
	●
	provide that Special Meetings of Gemini’s stockholders may be called by the Board pursuant to a resolution adopted by a majority of the total number of authorized directors;

	 
	 
	 

   

  			
	 
	●
	provide that the Board is divided into three classes of directors, with the classes to be as nearly equal as possible, and with the directors serving three-year terms, therefore making it more difficult for stockholders to change the composition of our Board; and

	 
	 
	 

   

  			
	 
	●
	do not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.

   

  The combination of these provisions will make it more difficult for the existing stockholders to replace the Board as well as for another party to obtain control of Gemini by replacing the Board. Because the Board has the power to retain and discharge its officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for the Board to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.

   

  These provisions are intended to enhance the likelihood of continued stability in the composition of the Board and its policies and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce Gemini’s vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for Gemini’s shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock.

   

  Delaware Anti-Takeover Law

   

   

  

   

  We have opted out of Section 203 of the DGCL. Section 203 of the DGCL prohibits a Delaware corporation from engaging in a “business combination” with an “interested stockholder” (i.e. a stockholder owning 15% or more of company’s voting stock) for three years following the time that the “interested stockholder” becomes such, subject to certain exceptions.

  Limitations on Liability and Indemnification of Officers and Directors

   

  The Certificate of Incorporation limits the liability of the directors of Gemini to the fullest extent permitted by the DGCL, and the Bylaws provide that we will indemnify them to the fullest extent permitted by such law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our Board. Under the terms of such indemnification agreements, we are required to indemnify each of our directors and officers, to the fullest extent permitted by the laws of the state of Delaware, if the basis of the indemnitee’s involvement was by reason of the fact that the indemnitee is or was a director or officer of Gemini or any of its subsidiaries or was serving at Gemini’s request in an official capacity for another entity. We must indemnify our officers and directors against all reasonable fees, expenses, charges and other costs of any type or nature whatsoever, including any and all expenses and obligations paid or incurred in connection with investigating, defending, being a witness in, participating in (including on appeal), or preparing to defend, be a witness or participate in any completed, actual, pending or threatened action, suit, claim or proceeding, whether civil, criminal, administrative or investigative, or establishing or enforcing a right to indemnification under the indemnification agreement. The indemnification agreements also require us, if so requested, to advance within 10 days of such request all reasonable fees, expenses, charges and other costs that such director or officer incurred, provided that such person will return any such advance if it is ultimately determined that such person is not entitled to indemnification by us. Any claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

   

  Exclusive Jurisdiction of Certain Actions

   

  The Bylaws require, to the fullest extent permitted by law, unless Gemini consents in writing to the selection of an alternative forum, that derivative actions brought in the name of Gemini, actions against directors, officers and employees for breach of fiduciary duty, actions asserting a claim arising pursuant to any provision of the DGCL or the Certificate of Incorporation or the Bylaws, actions to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws and actions asserting a claim against Gemini governed by the internal affairs doctrine may be brought only in the Court of Chancery in the State of Delaware and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder’s counsel. Although we believe this provision benefits Gemini by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers.

   

  In addition, the Bylaws require that, unless Gemini consents in writing to the selection of an alternative forum, the United States District Court for the District of Massachusetts shall be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act. Gemini has chosen the United States District Court for the District of Massachusetts as the exclusive forum for such Securities Act causes of action.

   

  Transfer Agent

   

  The transfer agent for our common stock is Continental Stock Transfer & Trust Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]